PCSK9 Manipulates Lipid Metabolism and the Immune Microenvironment in Cancer

Area of Science:

• Oncology
• Immunology
• Metabolic research

Background:

• Cancer is a leading global cause of death, with immunotherapy showing significant promise.
• Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of plasma lipid levels.
• Emerging evidence highlights PCSK9's role in cancer biology and immune modulation.

Purpose of the Study:

• To comprehensively review the multifaceted roles of PCSK9 in cancer.
• To elucidate the mechanisms by which PCSK9 influences tumorigenesis, progression, immune escape, and drug resistance.
• To highlight PCSK9 as a potential therapeutic target in oncology.

Main Methods:

• Literature review of preclinical and clinical studies on PCSK9 in cancer.
• Analysis of PCSK9's impact on lipid metabolism and immune cell signaling pathways.
• Synthesis of current knowledge on PCSK9's involvement in tumor development and treatment resistance.

Main Results:

• PCSK9 modulates immune responses during tumor progression via lipid metabolism.
• PCSK9 influences the fate and function of various immune cells (e.g., inflammatory, MHC, TCR signaling).
• PCSK9 is implicated in cancer immune escape and acquired drug resistance.

Conclusions:

• PCSK9 plays a significant, previously underappreciated role in cancer immunity and progression.
• Targeting PCSK9 may offer novel strategies to enhance cancer immunotherapy and overcome resistance.
• Further research into PCSK9's immunomodulatory functions is warranted for clinical translation.